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Objectives. The aim of the study was to assess the prognostic
value of myocardial viability and ischemia detected by dobutamine
stress echocardiography (DSE) in patients with acute myocardial
infarction (AMI) treated with thrombolysis.
Background. DSE can detect myocardial viability and ischemia
early after AMI, but the prognostic importance of viability and
ischemia in these patients has yet to be assessed.
Methods. DSE was performed in 152 patients at a mean of 9 6
5 days after a first AMI treated with thrombolysis to evaluate
myocardial viability and ischemia. The patients were followed up
for 15 6 19 months.
Results. On the basis of DSE results three groups of patients
were identified: group 1 (95 patients, 62.5%) with myocardial
viability and ischemia, group 2 with myocardial viability without
ischemia (32 patients, 21%) and group 3 (25 patients, 16.5%) with
no myocardial viability. During follow-up 10 patients (6.5%) had
hard events, 53 (35%) developed unstable angina and 67 (44%)
underwent myocardial revascularization. The rate of hard events
was 10% in group 1 and 0% in group 2 and 3 patients (p < 0.05
group 1 versus group 2); group 1 patients with viability and
ischemia showed a significantly higher rate of recurrence of
unstable angina and myocardial revascularization procedures
(40% and 60%) compared to group 2 (22% and 16%) and group 3
patients (20% and 20%). Using the Cox multivariate stepwise
model, only the extent of ischemic myocardium (hazard ratio
(HR) 5 21.7, p 5 0.02) and angina during DSE (HR 5 4.45, p 5
0.03) were significant predictors of hard events; an ischemic
response to DSE (HR 5 2.92, p 5 0.001) was the most important
predictor of spontaneous events, followed by ST-segment depres-
sion during DSE (HR 5 1.71, p 5 0.04), angina during DSE
(HR 5 1.53, p 5 0.19) and age (HR 5 0.96, p 5 0.05).
Conclusions. In patients with a first AMI treated with throm-
bolysis the presence and extent of myocardial ischemia during
DSE is the most important predictor of both hard and spontane-
ous cardiac events, whereas myocardial viability does not have an
independent prognostic value.
(J Am Coll Cardiol 1998;32:380–6)
©1998 by the American College of Cardiology
In survivors of acute myocardial infarction (AMI) early assess-
ment of prognosis is of major importance for identifying
patients at high risk of subsequents events and guiding thera-
peutic decisions. Several studies in the prethrombolytic era
showed that impaired left ventricular (LV) function, multives-
sel coronary disease and the presence of inducible ischemia are
the most important predictors of an adverse outcome after
AMI (1–4). Thrombolytic treatment has improved the prog-
nosis of patients with AMI through its potential to salvage
viable myocardium at risk in the infarct zone, reduce infarct
size and improve LV function (5–8); however, viable but
jeopardized myocardium supplied by a critical residual coro-
nary stenosis can be at increased risk of further ischemic events
and adversely affect prognosis.
Dobutamine stress echocardiography (DSE) offers the
unique opportunity of evaluating both myocardial viability and
ischemia early after AMI (9–12); however, recent studies in
patients with AMI or postinfarction LV dysfunction (11,13–15)
have led to conflicting results on the prognostic significance of
myocardial viability and ischemia detected by DSE. Thus, the
purpose of this study was to assess the prevalence and clinical
correlates of myocardial viability and ischemia detected by
DSE and to evaluate prospectively their prognostic importance
in patients with a first AMI treated with thrombolysis.
Methods
Study population. The initial study population was com-
posed of 181 consecutive patients admitted to our Coronary
Care Unit who fulfilled the following prospectively defined
selection criteria: 1) first episode of AMI diagnosed on the
basis of chest pain of .30 min, evolutionary ST-segment and
T-wave changes and an increase in creatine kinase and MB
fraction serum levels to at least twice the upper limits of
normal values; 2) intravenous thrombolysis within 6 h from
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onset of chest pain; 3) age #70 years; and 4) no life-limiting
systemic disease. Of the 181 patients initially eligible for the
study, 5 (2.8%) died and 16 (8.8%) developed early complica-
tions and therefore, were excluded from the study; 8 patients
(4.4%) had a poor echocardiographic window in baseline
conditions, and were also excluded. The final study population
consisted of 152 patients with a first AMI treated with throm-
bolysis who had no major in-hospital complications and a
satisfactory baseline echocardiographic examination.
Dobutamine stress echocardiography. The test was per-
formed at a mean of 9 6 5 days (range 6 to 15 days) after AMI.
The study protocol was approved by the local institutional
committee on human research and all patients gave written
informed consent. Dobutamine was administered according to
a previously described protocol (13,15), including atropine
administration if the test was negative at the 40 mg/kg/min dose
and heart rate did not reach 85% of maximal age-predicted
heart rate. End points of the test have been described in detail
elsewhere (10,13). Using a commercially available ultrasound
imaging equipment (Sonos 1000, Hewlett-Packard) two-
dimensional images in parasternal long- and short-axis and
apical four- and two-chamber views were obtained at baseline,
at each step of DSE and during recovery and recorded on a
super-VHS videotape for subsequent analysis. In addition to
videotape recording, in the last 90 patients selected cardiac
cycles at baseline, 10 mg/kg/min dobutamine dosage, peak
stress and recovery were digitized on-line and compared
off-line in a cine-loop mode using a quad-screen display.
Echocardiographic analysis. All examinations were re-
viewed by two independent observers blinded to the clinical
data of the patients. For LV wall motion analysis standard
16-segment model of the left ventricle of the American Society
of Echocardiography was used (16) and wall motion was scored
as 1 5 normal; 2 5 hypokinetic; 3 5 akinetic; 4 5 dyskinetic.
A LV wall motion score index (WMSI) was calculated at
baseline, low (10 mg/kg/min) and peak dobutamine dosage. LV
segments were grouped according to AMI and non-AMI zone
location; the site of AMI was defined as anterior, inferior or
lateral on the basis of the electrocardiographic changes in the
acute phase. Infarct zone was evaluated according to the
theoretical maximal risk area (17), which included nine seg-
ments for anterior AMI, six for inferior AMI and five for
lateral AMI. Apical inferior, apical lateral and basal and
midposterior segments were considered overlap segments.
A segment was defined as viable when during low-dose DSE
systolic wall thickening and endocardial motion appeared in a
basally akinetic or dyskinetic segment or normal or near-
normal wall motion and thickening became apparent in a
severely hypokinetic segment. Myocardial viability was consid-
ered to be present in the infarct zone when the improvement
involved at least two segments or at least one segment when
only two were basally asynergic. The diagnosis of DSE-induced
myocardial ischemia in the infarct zone was made when 1) a
basally akinetic or hypokinetic segment, after improving its
thickening and motion at low doses, showed a significant
deterioration at peak stress (biphasic response); 2) a basally
hypokinetic segment showed a direct deterioration to akinesia
or dyskinesia; and 3) a new asynergy developed in a basally
normal segment. Akinesia directly deteriorating to dyskinesia
was not thought to be indicative of ischemia. Ischemia at a
distance was diagnosed when a new or worsening asynergy
developed in segments not included in and not contiguous to
the infarct zone. To provide a semiquantitative estimate of the
extent of viable and ischemic myocardium, the difference
between basal and low-dose DSE WMSI, which estimates the
extent of viable myocardium, and the difference between peak
stress and low-dose DSE WMSI, which estimates the extent of
ischemic myocardium, were calculated.
Follow-Up. Follow-up data were obtained through review
of the patient’s hospital record, periodic visits by a staff
physician in the outpatient clinic and telephone interview with
the patient by trained personnel. None of the patients was lost
to follow-up. The clinical events recorded were cardiac death,
nonfatal myocardial infarction and unstable angina, defined
according to previously published criteria (13). Because the
decision to perform revascularization procedures may not
reflect a clinical event, these procedures were considered
separately from spontaneous events; however, as revascular-
ization can affect patient outcome, follow-up was censored
after the procedure. Therefore, the outcome events were
analyzed as hard events (defined as cardiac death and nonfatal
AMI), spontaneous events (death, nonfatal AMI and unstable
angina) and total cardiac events (spontaneous events and
revascularization procedures). Only the initial event was con-
sidered for each patient and the follow-up was stopped at the
time of this event. The observation period was censored at last
assessment in event-free patients.
Statistical analysis. Results are given as mean value 6
standard deviation. Cumulative curves of survival were calcu-
lated by means of the product-limit method of Kaplan and
Meier. The individual effect of demographic, clinical and
echocardiographic variables on survival was evaluated with the
use of the Cox regression model (StataCorp. 1997, Stata
Statistical Software, release 5.0). All variables analyzed in the
study were first evaluated by univariate analysis using either log
rank test for categorical variables or Cox regression for con-
tinuous variables. Those variables that showed an association
with the outcome at a p level ,0.1 were included in the
multivariate Cox model, selected according to a backward
stepwise selection process and entered into or removed from
the regression equation on the basis of a computed significance
probability value. A p value ,0.05 was considered statistically
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
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381JACC Vol. 32, No. 2 PREVITALI ET AL.
August 1998:380–6 DOBUTAMINE STRESS ECHO AFTER THROMBOLYSED AMI
significant. Hazard ratio (HR) together with 95% confidence
intervals (CI) are given for the Cox models.
Differences in clinical variables between the three groups of
patients were evaluated by analysis of variance followed by
Scheffe´ test for continuous variables and by Pearson chi-square
test for categorical variables. Differences between paired data
were analyzed by Student’s paired t test; nonparametric differ-
ences were examined using a chi-square test. A p value of
,0.05 was considered significant.
Results
Study population. The study group consisted of 142 men
and 10 women, with a mean age of 54 6 8 years. The
electrocardiographic site of AMI was anterior in 78 patients
(51%) and inferior or inferolateral in 74 patients (49%); 112
patients (74%) had a Q-wave and 40 (26%) a non-Q wave
AMI. Mean peak creatine kinase was 2,140 6 1,614 IU/L and
was reached at a mean of 15 6 3 h after admission. Streptoki-
nase (1,500,000 U over 1 h) was administered to 45 patients,
alteplase (recombinant tissue-type plasminogen activator,
15 mg bolus followed by 50 mg over 1 h and 35 mg over 2 h) to
99 patients and saruplase (single-chain urokinase plasminogen
activator, 20 mg bolus followed by 60 mg over 1 h) to 8
patients.
Feasibility, safety and hemodynamic findings. The echo-
cardiographic images during DSE were considered interpret-
able in all patients. No major complication occurred during
DSE. Limiting side effects leading to the interruption of DSE
occurred in 7 patients (5%) and included increase in systolic
blood pressure to .230 mm Hg in five patients, symptomatic
sustained ventricular tachycardia in one patient and symptom-
atic hypotension in one patient. Compared to baseline values
heart rate, systolic blood pressure and double product in-
creased significantly at peak stress in all three groups. Fifteen
patients in group 1 (16%), 18 in group 2 (56%) and 11 in group
3 (44%) reached 85% of maximal age-predicted heart rate.
Dobutamine stress echocardiography. Interobserver con-
cordance was 98% (150 of 152 patients) for assessment of
baseline wall motion abnormalities, 94% (143 of 152 patients)
for evaluation of myocardial viability in the infarct zone and
92% (140 of 152 patients) for detection of myocardial isch-
emia. In case of disagreement, a consensus was reached.
On the basis of the response to DSE three groups of
patients were identified: group 1 included 95 patients (62.5%)
showing an ischemic response to DSE, group 2 was composed
of 32 patients (21%) showing myocardial viability in the infarct
zone without ischemia either in the infarct zone or at a distance
and group 3 included 25 patients (16.5%) with no evidence of
myocardial viability or ischemia. In group 1 mean baseline
WMSI decreased from 1.52 6 0.34 to 1.28 6 0.25 (p , 0.0001)
at low doses and then increased to 1.75 6 0.29 (p , 0.0001
versus baseline and low doses) at peak stress. In group 2 WMSI
decreased from 1.47 6 0.32 at baseline to 1.22 6 0.23 at low
doses (p , 0.0001) and did not change significantly at peak
stress (1.19 6 0.31); in group 3 it did not change significantly
from baseline (1.72 6 0.42) to low-dose dobutamine (1.72 6
0.42) and peak stress (1.75 6 0.45).
Of the 95 patients with an ischemic response to DSE (group
1), 83 (87%) had ischemia in the infarct zone only, 8 (8%)
showed ischemia both in the infarct zone and at a distance and
4 (4%) had only remote ischemia. Of the 91 patients with
ischemia in the infarct zone 82 (90%) showed a biphasic
response to DSE, whereas 9 (10%) showed a direct deteriora-
tion of regional wall motion from normokinesia or hypokinesia
to akinesia. The test was positive for myocardial ischemia at
the dose of 20 mg/kg/min or lower in 10 patients (10.5%), of
.20 mg/kg/min in 68 patients (71.5%) and after atropine in 17
patients (18%). During DSE a $1 mm ST-segment shift
developed in 46% of group 1, 25% of group 2 and 36% of
group 3 patients; 17% of group 1, 3% of group 2 and 8% of
group 3 patients had chest pain.
Comparison of clinical characteristics. The main clinical
characteristics of patients in the three groups are compared in
Table 1. Anterior AMI was more frequent in group 1 and
group 3 patients (56% and 64%) compared with group 2
patients (31%, p , 0.05). Group 3 patients with no myocardial
viability were older and had significantly higher peak creatine
kinase and baseline WMSI compared with the other two
groups.
Cardiac events during follow-up. During a follow-up of
15 6 19 months there were 10 hard events, which included 4
deaths and 6 nonfatal AMI; 53 patients developed unstable
angina and 67 underwent coronary bypass (16 patients) or
coronary angioplasty (51 patients). In 46 of 67 patients revas-
cularization was performed because of recurrence of angina.
Hard events occurred at a mean of 11 6 14 months after AMI
and unstable angina developed at a mean of 3 6 5 months. The
incidence of hard events, unstable angina, spontaneous events
and total cardiac events including revascularization procedures
in the three groups of patients is shown in Table 2. Cumulative
survival free of hard events of group 1 patients with viability
and ischemia was significantly lower (p , 0.05) than that of
Table 1. Clinical and Echocardiographic Findings in the Three
Groups of Patients Studied
Group 1 Group 2 Group 3
Age (yr) 54 6 8 52 6 7 58 6 10*
Sex (M/F) 88/7 30/2 24/1
Hypertension % (n) 25 (24/95) 31 (10/32) 24 (6/25)
Previous angina % (n) 12 (11/95) 9 (3/32) 16 (4/25)
Site of AMI % (n)
Anterior 56 (53/95) 28 (9/32)* 64 (16/25)
Inferior 43 (41/95) 69 (22/32) 36 (9/25)
Lateral 1 (1/95) 3 (1/32) 0
Non-Q AMI % (n) 32 (30/95) 22 (7/32) 12 (3/25)
Peak CK (IU/L) 2,014 6 1,544 1,789 6 1,340 3,024 6 1,903*
Baseline WMSI 1.52 6 0.34 1.47 6 0.32 1.72 6 0.42*
Beta-blockers % (n) 47 (45/95) 40 (13/32) 36 (9/25)
Nitrates % (n) 38 (36/95) 56 (18/32) 56 (14/25)
Calcium antagonists % (n) 16 (15/95) 6 (2/32) 8 (2/25)
WMSI 5 wall motion score index; *p , 0.05 versus other groups.
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group 2 patients with viability without ischemia, whereas the
difference did not attain statistical significance (p 5 0.06) in
comparison with group 3 patients without viability (Fig. 1).
Hard events were observed in 3 of 10 patients with a positive
response at a dosage of #20 mg/kg/min and in 7 of 85 with a
positive response at higher doses (30% versus 8%, p , 0.05).
The incidence of hard events was not different in patients with
ischemia in the infarct zone and in those with remote ischemia
(10% versus 17%). Sensitivity, specificity, positive and negative
value of DSE for prediction of hard events were 100%, 40%,
9% and 100%, respectively.
As shown in Figure 2, cumulative survival rate free of
spontaneous events in group 1 with myocardial ischemia
during DSE was significantly lower in comparison with group 2
(p , 0.002) and group 3 (p , 0.005), whereas no significant
difference was found between groups 2 and 3. Seven of 10
patients (70%) with an ischemic response at a dose of #20
mg/kg/min and 34 of 85 patients (40%) with a positive response
at a .20 mg/kg/min dosage had unstable angina. Therefore,
spontaneous events were significantly more frequent in pa-
tients with a positive response at a #20 mg/kg/min dose than in
those with positivity at higher doses (100% versus 48%, p ,
0.01). Unstable angina developed more frequently in patients
with remote ischemia than in those with a positive response in
the infarct zone, but the difference was not statistically signif-
icant (58% versus 41%). When all cardiac events, including
myocardial revascularization procedures when they occurred
as a first event, were considered, group 1 patients with
myocardial ischemia at DSE had an all event-free survival rate
significantly lower than that of group 2 (p , 0.0001) and group
3 (p , 0.001) patients, whereas no significant difference was
found between groups 2 and 3. Sensitivity, specificity, positive
and negative value of DSE were 81%, 51%, 54% and 79% for
prediction of spontaneous events and 82%, 62%, 72% and
74% for prediction of total cardiac events, respectively.
Prognostic analysis. The univariate and multivariate prog-
nostic factors for cardiac events are shown in Table 3. The
most important univariate predictor of hard events was posi-
tivity of DSE for myocardial ischemia, followed by the WMSI
at peak stress, the difference between WMSI at peak stress and
WMSI at low-dose DSE and angina during DSE. For sponta-
neous events, the most significant predictor was positivity of
DSE for myocardial ischemia followed by the difference be-
tween peak stress and low-dose DSE WMSI and by the peak
stress WMSI. At multivariate analysis only the extent of
ischemic myocardium, expressed as the difference between
peak stress and low-dose DSE WMSI and angina during DSE
remained statistically significant independent predictors of
hard events. Difference between peak WMSI and low-dose
DSE WMSI was 0.53 6 0.24 in patients with hard events and
0.27 6 0.27 in those without hard events. For spontaneous
events, positivity of DSE for myocardial ischemia was the
strongest independent predictor, followed by ST-segment de-
pression during test, angina during DSE and age.
Discussion
Prognostic significance of myocardial ischemia. In post-
AMI patients stress-induced myocardial ischemia has been
recognized as a strong predictor of future cardiac events in the
prethrombolytic era (18–20), but its prognostic value in pa-
tients receiving thrombolytic treatment is still controversial
Table 2. Cardiac Events During Follow-up in the Three Groups
of Patients
Group 1
(n 5 95)
Group 2
(n 5 32)
Group 3
(n 5 25)
Death 4 (4.2%) 0 0
AMI 6 (6.3%) 0 0
Hard events 10 (10.5%) 0 0
Unstable angina 41 (43%) 7 (22%) 5 (20%)
Spontaneous events 51 (54%) 7 (22%) 5 (20%)
Total events 69 (72%) 8 (25%) 7 (28%)
AMI 5 acute myocardial infarction.
Figure 1. Kaplan-Meier event-free
survival curves for hard events in
patients with myocardial viability and
ischemia (group 1), myocardial via-
bility without ischemia (group 2) and
no myocardial viability (group 3) dur-
ing dobutamine stress echocardiogra-
phy. Cumulative survival free of hard
events was significantly lower (p ,
0.05) in group 1 compared to group 2
patients, whereas the difference be-
tween group 1 and group 3 did not
reach statistical significance.
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(6,13,15,21–24). The results of this study show that in patients
treated with thrombolysis the presence and extent of myocar-
dial ischemia detected by DSE is the most important predictor
of hard events and recurrence of unstable angina, whereas
myocardial viability does not show an independent prognostic
value. An ischemic response to DSE was associated with a 9%
rate of hard events and a significantly higher rate of unstable
angina and revascularization procedures during the follow-up,
whereas no hard events occurred in patients without myocar-
dial ischemia during DSE, irrespective of the presence or
absence of myocardial viability. Our results are in keeping with
several studies using exercise (25), dipyridamole (24,26) and
dobutamine (11,15) stress echocardiography, which have
shown that patients with positive results early after AMI have
a significantly higher incidence of reinfarction and unstable
angina than patients with negative results; moreover, it has
been shown that stress echocardiography can predict the site of
AMI up to 1 year after the test (27).
In the present study DSE detected myocardial ischemia
more frequently within the infarct zone than at a distance;
remote ischemia was documented in only 13% of patients with
a positive DSE and did not emerge as a significant predictor of
events. Our results are in agreement with those reported by
Dakik et al. (28), who showed that in a population treated with
Figure 2. Kaplan-Meier event-free
survival curves for spontaneous events
in patients with myocardial viability
and ischemia (group 1), myocardial
viability without ischemia (group 2)
and no myocardial viability (group 3)
during dobutamine stress echocardi-
ography. Cumulative survival free of
spontaneous events was significantly
lower in group 1 patients compared to
group 2 (p , 0.002) and group 3
patients (p , 0.005), whereas no dif-
ference was present between group 2
and 3.
Table 3. Univariate and Multivariate Predictors of Hard Events, Spontaneous Events and Total Events
Univariate Analysis
Chi-square
test
p
Value Multivariate analysis
p
Value HR (95% CI)
Hard events Hard events
Ischemia at DSE 7.65 0.006 Peak stress-low dose WMSI D 0.02 21.7 (1.69–279)
Peak stress WMSI 7.38 0.007 Angina during DSE 0.03 4.45 (1.13–17.5)
Peak stress-low dose WMSI D 9.46 0.002
Angina during DSE 12.8 0.0003
Spontaneous events Spontaneous events
Ischemia at DSE 14.8 0.0001 Ischemia at DSE 0.001 2.92 (1.52–5.59)
Peak stress-low dose WMSI D 10 0.002 ST depression during DSE 0.04 1.71 (1.02–2.85)
Peak stress WMSI 9 0.003 Angina during DSE 0.2 1.53 (0.80–2.93)
ST depression during DSE 8.71 0.003 Age 0.05 0.96 (0.93–0.99)
Baseline WMSI 5.29 0.02
Angina during DSE 4.81 0.03
Total events Total events
Ischemia at DSE 22.6 0.0000 Ischemia at DSE 0.000 3.56 (1.86–6.78)
Peak stress-low dose WMSI D 18.95 0.0000 ST depression during DSE 0.06 1.5 (0.98–2.35)
Viability and ischemia during DSE 17.17 0.0002 Myocardial viability at DSE 0.09 0.51 (0.80–19.3)
Peak stress WMSI 13.15 0.0003 Baseline-low dose WMSI D 0.09 3.94 (0.23–1.13)
ST depression during DSE 8.06 0.004
Baseline-low dose WMSI D 7.52 0.006
Baseline WMSI 4.98 0.003
Age 4.01 0.04
CI 5 confidence intervals; DSE 5 dobutamine stress echocardiography; HR 5 hazard ratio; WMSI 5 wall motion
score index; D 5 difference.
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thrombolysis, 70% of patients with scintigraphic evidence of
ischemia had it localized in the infarct zone only and found
that the presence of infarct-zone redistribution was a signifi-
cant predictor of cardiac events. In patients with a first AMI
also Sicari and al. (13) and Greco and al. (15) detected
myocardial ischemia by DSE more frequently in the infarct
zone than at a distance. On the other hand, in the study by
Carlos and al. (11) rest or dobutamine-induced asynergy
outside the infarct zone was found in a higher proportion of
cases compared to the previously reported studies and was an
independent predictor of an adverse outcome. This discrep-
ancy is probably related to the high prevalence of multivessel
disease (54%) in the population studied by Carlos et al.;
moreover, early revascularization of the infarct-related coro-
nary artery was carried out in 29% of their patients and may
have prevented the adverse influence of periinfarction isch-
emia on prognosis. In our study the extent of ischemic myo-
cardium at peak DSE and positivity of DSE at a dose #20
mg/kg/min were significantly correlated with both hard and
spontaneous events. These findings are in keeping with recent
studies showing that the severity and extent of stress-induced
myocardial ischemia can effectively stratify patients into high-
and low-risk groups (24,28,29).
In this study DSE showed a high negative predictive value
for both hard and spontaneous cardiac events and therefore,
could be useful to identify patients at low risk of subsequent
events. On the other hand, in keeping with the low positive
predictive value reported by Greco et al. (15) for DSE (11%)
and by Picano et al. (24) for dipyridamole (6%), the specificity
and positive predictive value of DSE for hard events were only
40% and 9%.
Prognostic significance of myocardial viability. In this
study a significant minority of patients (21%) showed myocar-
dial viability in the infarct zone with no detectable ischemia
during DSE. The absence of inducible ischemia in an infarcted
region showing viability could be explained by the fact that the
coronary artery supplying this region has no residual critical
stenosis. This hypothesis is supported by angiographic studies
in AMI, which showed that early after thrombolysis a percent-
age of patients ranging from 10% (30) to 47% (31) has a ,60%
stenosis of the infarct-related coronary artery. In our study
patients showing myocardial viability without ischemia had an
excellent prognosis, with an incidence of hard events and
recurrence of angina significantly lower than that of patients
with ischemia and similar to that of patients without viability.
Thus, these patients should be distinguished from those show-
ing viability and ischemia for both prognostic and therapeutic
purposes. The results of our study are at variance with the
findings of previous studies showing that myocardial viability
detected by positron emission tomography (32,33) or DSE
(13,14) had an adverse influence on prognosis. However, these
studies evaluated different populations, characterized by
chronic coronary artery disease and severe LV dysfunction
(14,32,33) or did not assess separately the prognosis of post-
AMI patients showing viability with or without ischemia (13).
Thus, further studies are needed to better define the prognos-
tic role of myocardial viability in different subsets of patients
with variable degrees of LV dysfunction and chronic or acute
coronary artery disease.
Study limitations. The study population was composed of
selected patients with a first AMI treated with thrombolysis
and preserved or mildly impaired LV function. Thus, the study
results cannot be applied to the general population of patients
with AMI, of whom 15% to 30% had a previous AMI and a
significant proportion does not receive thrombolytic therapy.
At the time of DSE 44% of patients were treated with
beta-adrenergic blocking agents, which could have interfered
with detection of both myocardial viability and ischemia.
However, this finding reflects a common clinical practice, as
withdrawal of beta-blockers would be unpractical or even
controindicated early after AMI. Finally, coronary angiogra-
phy was performed only in a minority of patients and therefore,
its prognostic value was not investigated. The prognostic value
of coronary angiography after AMI is well established, but the
procedure may not be feasible and cost effective in all patients
with a first uncomplicated AMI.
Clinical implications. Patients showing myocardial viabil-
ity and ischemia early after a first AMI treated with thrombol-
ysis are at higher risk of hard events and recurrence of angina,
whereas those showing either viability without ischemia or no
residual viability in the infarct zone have a good prognosis and
could be managed initially with medical treatment. Owing to
its high negative predictive value DSE can be useful for an
accurate early identification of patients at low risk of subse-
quent cardiac events; on the other hand, its low positive
predictive value for hard events suggests that a further strati-
fication of patients with an ischemic response to DSE based on
the extent of ischemia and dose of dobutamine at which
ischemia develops is necessary to identify patients at higher
risk of events who require early aggressive treatment.
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